Delgocitinib: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Delgocitinib: clinical details
Prescribing considerations
- Initiation and supervision should be by a physician experienced in diagnosing and treating chronic hand eczema.
- Confirm moderate to severe chronic hand eczema and that topical corticosteroids are inadequate or inappropriate.
- Safety and efficacy have not been established below 18 years.
- Minimise mucous-membrane contact and counsel about the significant fabric fire hazard.
Contraindications and cautions
- Hypersensitivity to delgocitinib or any excipient.
- Use caution if an excipient-related local reaction is suspected; benzyl alcohol, butylhydroxyanisole and cetostearyl alcohol can cause irritation or contact reactions.
Monitoring
- Assess clinical response and local tolerability.
- Periodically examine the application site, particularly in people with skin-cancer risk factors, because non-melanoma skin cancer has been reported with topical JAK inhibitors.
- Encourage reporting of suspected adverse reactions through the MHRA Yellow Card scheme because the product is under additional monitoring.
Clinical pharmacology
A topical pan-JAK inhibitor acting on JAK1, JAK2, JAK3 and TYK2, attenuating JAK–STAT signalling by multiple pro-inflammatory cytokines. Systemic exposure after topical use is minimal.
Formulation and product differences
- The selected product is a white to slightly brown cream for cutaneous use.
- It contains benzyl alcohol, butylhydroxyanisole and cetostearyl alcohol, which may contribute to local irritation or allergic reactions.
- Do not freeze; discard according to the product instructions after opening.
Delgocitinib preparations and strengths
Cream
Route: Cutaneous
Strengths: 20 mg/g
Delgocitinib interactions
Formal clinical interaction studies have not been performed. Systemic interactions are considered unlikely because absorption through treated skin is minimal.
Other topical medicines or skin products
Use on the same treated area has not been adequately evaluated, so co-application is not recommended unless the prescriber advises otherwise.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.